NVDA
NVIDIA
-- 142.620 TSLA
Tesla
-- 406.580 PLTR
Palantir
-- 78.980 RGTI
Rigetti Computing
-- 13.2000 MSTR
MicroStrategy
-- 353.670 
Update
$Geron (GERN.US)$ Reuters
3 mins ago
Geron Announces Phase 1 Findings From Two-Part Improvemf Study Presented at Ash Suggesting Tolerability of Rytelo™ (Imetelstat) in Combination With Ruxolitinib as Frontline Therapy in Patients With Myelofibrosis
3 mins ago
Geron Announces Phase 1 Findings From Two-Part Improvemf Study Presented at Ash Suggesting Tolerability of Rytelo™ (Imetelstat) in Combination With Ruxolitinib as Frontline Therapy in Patients With Myelofibrosis
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Discussing
Trump 2.0 Era: What's the next opportunity in the markets?
▪️Could Trump's crypto policies potentially benefit the crypto market? ▪️Might his tariff policies have a positive effect on Chinese stocks
Michael McCarthy CCO
Jan 3 11:57
Ask a strategist - Trump's first day